Virpax Pharmaceuticals (Nasdaq:VRPX) announced today that it will pursue a direct to over-the-counter (OTC) regular pathway for Epoladerm. Berwyn, Pennsylvania–based Virpax designed the Epoladerm investigational pre-filled topical spray analgesic product for the non-addictive management of chronic pain associated with osteoarthritis (OA) of the knee. According to a news release, the company expects the direct to […]
Virpax Pharmaceuticals
Virpax completes FDA-required preclinical studies for pain-treating topical spray
Virpax Pharmaceuticals (Nasdaq:VRPX) announced today that it completed all FDA-required preclinical studies for its Epoladerm product. Berwyn, Pennsylvania-based Virpax designed its Epoladerm investigational pre-filled topical spray analgesic product for the non-addictive management of chronic pain associated with osteoarthritis (OA) of the knee. Its completed investigational new drug application (IND)-enabling studies included dermal toxicity, sensitization, irritation, […]
Virpax touts study results for intranasal spray for treating acute, chronic pain
Virpax Pharmaceuticals (NSDQ:VRPX) today announced promising results from preclinical studies for its Envelta intranasal spray. Berwyn, Pennsylvania-based Virpax designed Envelta (NES100), an endogenous enkephalin intranasal spray, for treating acute and chronic pain, including pain associated with cancer. According to a news release, findings from preclinical dose range-finding studies for Envelta complement previous positive preclinical toxicology […]
Virpax reports positive non-human study results for topical spray film that treats chronic pain
Virpax Pharmaceuticals (NSDQ:VRPX) today reported positive results from a study of its Epoladerm treatment for chronic pain management. Berwyn, Pennsylvania-based Virpax designed Epoladerm, one of its lead investigational products, for managing pain associated with osteoarthritis of the knee. According to a news release, the company reported positive results following the completion of a toxicology and […]
Drug delivery tech developer Virpax Pharmaceuticals prices $40M offering
Virpax Pharmaceuticals (NSDQ:VRPX) announced today that it priced an underwritten public offering worth approximately $40 million. Berwyn, Pennsylvania-based Virpax’s offering includes 6.67 million shares of common stock priced at $6 per share, totaling just over $40 million before deducting underwriting discounts and offering expenses. Additionally, the company granted underwriters a 45-day option to purchase up […]
